secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-07-09T21:10:23+00:00
Accession:  0001438533-26-000054
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics CAO Sandra Calvin to retire; John Torell to succeed
------------------------------------------------------------------------

- Sandra Calvin to retire as CAO/PAO after filing 10-K expected in February 2027.
- John Torell, current VP Controller, to be appointed CAO/PAO before retirement date.
- Torell joined Travere in 2021; previously VP Controller at Pacific Life and audit manager at Deloitte.
- Torell holds CFA and CPA designations; transition plan aims for orderly handover.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/0001438533-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/tvtx-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer